Sequenom Forms In-Network Contracts
News May 04, 2016
Sequenom, Inc. has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).
The agreements provide in-network coverage for Sequenom Laboratories™' noninvasive prenatal tests for both high and average-risk pregnancies to Anthem's members in those states. The Georgia agreement does not include HMO plans, and the Virginia agreement does not include HealthKeepers products.
"Becoming an in-network provider with leading health insurers, particularly for average risk pregnancies, is a critical component of our commercialization plan," said Dirk van den Boom, Ph.D., President and CEO of Sequenom. "The addition of these seven states to our Anthem Blue Cross and Blue Shield relationship represents meaningful progress in our efforts to bring the benefits of noninvasive prenatal testing to women throughout the United States."
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE